Free Trial

Atyr PHARMA Q3 2023 Earnings Report

Atyr PHARMA logo
$4.32 -0.11 (-2.48%)
As of 02/21/2025 04:00 PM Eastern

Atyr PHARMA EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Atyr PHARMA Revenue Results

Actual Revenue
$0.35 million
Expected Revenue
$6.00 million
Beat/Miss
Missed by -$5.65 million
YoY Revenue Growth
N/A

Atyr PHARMA Announcement Details

Quarter
Q3 2023
Time
N/A

Atyr PHARMA Earnings Headlines

Atyr PHARMA (NASDAQ:ATYR) Stock Rating Upgraded by Leerink Partnrs
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Analysts at Leerink Partners
Trump doesn’t give a damn
Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…
RBC Capital Keeps Their Buy Rating on aTyr Pharma (ATYR)
See More Atyr PHARMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atyr PHARMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atyr PHARMA and other key companies, straight to your email.

About Atyr PHARMA

Atyr PHARMA (NASDAQ:ATYR), Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

View Atyr PHARMA Profile

More Earnings Resources from MarketBeat